Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207

Jonathan R. Walker, Kevin G. McGeagh, Periasamy Sundaresan, Timothy J. Jorgensen, Samuel D. Rabkin, Robert L. Martuza

Research output: Contribution to journalArticle

Abstract

Prostate adenocarcinoma is the most common nonskin malignancy in males and the second most common cause of cancer death in the United States (Landis et al., 1998). Initial treatments of surgery or radiotherapy may cause impotence and/or incontinence from neural damage (Eastham and Scardino, 1998; Porter et al., 1998). When extraprostatic or metastatic disease develops, castration or pharmaceutical androgen ablation is utilized (Catalona, 1994). Androgen-resistant recurrence indicates a poor prognosis and justifies experimental chemotherapy (Oh and Kantoff, 1998). G207 (Mineta et al., 1995; Yazaki et al., 1995) is a multimutated herpes simplex virus 1 (HSV) vector that replicates within cancer cells, causing cellular death; however, replication is limited in normal cells, including those of the nervous system. In vitro, G207 at a low multiplicity of infection (MOI of 0.01) is oncolytic for multiple human prostate cancer cells. In athymic mice, a single intraneoplastic inoculation of G207 completely eradicates >22% of established subcutaneous human prostate cancer tumors irrespective of hormonal responsiveness. Two intraneoplastic inoculations of G207 completely eradicated two of three recurrent previously irradiated tumors and two intravenous administration of G207 induced tumor regression in distant subcutaneous tumors and completely eradicated one-fourth of the tumors.

Original languageEnglish (US)
Pages (from-to)2237-2243
Number of pages7
JournalHuman gene therapy
Volume10
Issue number13
DOIs
StatePublished - Sep 1 1999

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207'. Together they form a unique fingerprint.

  • Cite this

    Walker, J. R., McGeagh, K. G., Sundaresan, P., Jorgensen, T. J., Rabkin, S. D., & Martuza, R. L. (1999). Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Human gene therapy, 10(13), 2237-2243. https://doi.org/10.1089/10430349950017211